HUTCHMED (China) (HKG:0013) reported an attributable net income of $37.7 million in 2024, down from $100.8 million a year earlier.
Earnings per share were $0.04, a decline from $0.12 in the same period last year, according to a Wednesday filing with the Hong Kong bourse.
Revenue dropped to $630.2 million from $838.0 million the previous year.
Looking ahead, the biotech firm expects to generate a consolidated revenue of $350 million to $450 million for its oncology and immunology business.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。